1Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology, 2004, 126: 322～342. 被引量：1
2Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol, 2005, 39 (4 Suppl 2): S111～S124. 被引量：1
3Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology, 2002, 36: 525～531. 被引量：1
4Socha P, Koletzko B, Pawlowska J, Socha J. Essential fatty acid status in children with cholestasis, in relation to serum bilirubin concentration. J Pediatr, 1997, 131:700～706. 被引量：1
5Abdel-GhaffarYT, Amin E, Abdel-Rasheed M, Fouad HH. Essential fatty acid status in infants and children with chronic liver disease. East Mediterr Health J, 2003,9: 61～69. 被引量：1
6Socha P, Koletzko B, Jankowska I, Pawlowska J, Demmelmair H, Stolarczyk A, Swiatkowska E, Socha J. Longchain PUFA supplementation improves PUFA profile in infants with cholestasis. Lipids, 2002, 37: 953～957. 被引量：1
7Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A doubleblind, placebo-controlled study. Gastroenterology, 1990,99:211～215. 被引量：1
8Bray GP, Tredger JM, Williams R. Resolution of danazolinduced cholestasis with S-adenosylmethionine. Postgrad Med J, 1993, 69: 237～239. 被引量：1
